Genes,
Journal Year:
2023,
Volume and Issue:
14(6), P. 1160 - 1160
Published: May 26, 2023
Breast
cancer
is
the
most
frequently
diagnosed
malignancy
worldwide
and
leading
cause
of
cancer-related
death
among
women.
Brain
metastases
are
a
primary
contributor
to
mortality,
as
they
often
go
undetected
until
late
stages
due
their
dormant
nature.
Moreover,
clinical
management
brain
complicated
by
relevant
issue
blood-brain
barrier
penetration.
The
molecular
pathways
involved
in
formation,
progression,
colonization
breast
tumors
subsequent
diverse,
posing
significant
hurdles
heterogeneous
nature
subtypes.
Despite
advancements
treatments,
prognosis
for
patients
with
remains
poor.
In
this
review,
we
aim
highlight
biological
mechanisms
evaluating
multi-step
genetic
discuss
currently
available
emerging
treatment
strategies
propose
prospective
overview
complex
disease.
Cancer Cell,
Journal Year:
2024,
Volume and Issue:
42(3), P. 378 - 395.e10
Published: Jan. 21, 2024
Brain
metastasis
(BrM)
is
a
common
malignancy,
predominantly
originating
from
lung,
melanoma,
and
breast
cancers.
The
vasculature
key
component
of
the
BrM
tumor
microenvironment
with
critical
roles
in
regulating
metastatic
seeding
progression.
However,
heterogeneity
major
vascular
components,
namely
endothelial
mural
cells,
still
poorly
understood.
We
perform
single-cell
bulk
RNA-sequencing
sorted
cell
types
detect
multiple
subtypes
enriched
specifically
compared
to
non-tumor
brain,
including
previously
unrecognized
immune
regulatory
subtypes.
integrate
human
data
mouse
models,
creating
platform
interrogate
targets
for
treatment
BrM.
find
that
CD276
checkpoint
molecule
significantly
upregulated
vasculature,
anti-CD276
blocking
antibodies
prolonged
survival
preclinical
trials.
This
study
provides
important
insights
into
complex
interactions
between
cancer
translational
relevance
designing
therapeutic
interventions.
Critical Reviews in Oncology/Hematology,
Journal Year:
2024,
Volume and Issue:
196, P. 104295 - 104295
Published: Feb. 20, 2024
The
development
of
targeted
therapy
in
epidermal
growth
factor
receptor
(EGFR)-mutated
non-small
cell
lung
cancer
(NSCLC)
patients
has
radically
changed
their
clinical
perspectives.
Current
first-line
standard
treatment
for
advanced
disease
is
commonly
considered
third-generation
tyrosine
kinase
inhibitors
(TKI),
osimertinib.
study
primary
and
acquired
resistance
to
front-line
osimertinib
one
the
main
burning
issues
further
improve
patients'
outcome.
Great
heterogeneity
been
depicted
terms
duration
benefit
pattern
progression
this
might
be
related
molecular
factors
including
subtypes
EGFR
mutations
concomitant
genetic
alterations.
Acquired
can
categorized
into
two
classes:
EGFR-dependent
EGFR-independent
mechanisms
specific
have
demonstrated.
purpose
manuscript
provide
a
comprehensive
overview
literature
about
osimertinib,
from
perspective
therefore
relationship
emerging
therapeutic
approaches.
Advanced Intelligent Systems,
Journal Year:
2024,
Volume and Issue:
6(5)
Published: April 21, 2024
Surgical
robot
systems
(SRS)
represent
an
innovative
cross‐disciplinary
research
field
using
robotic
technology
to
assist
surgeons
in
operations.
Current
bottlenecks
SRS,
such
as
the
limited
ability
process
complex
information
and
make
surgical
decisions,
have
not
been
effectively
solved.
Artificial
intelligence
(AI)
is
a
valuable
technique
for
simulating
extending
human
intelligence.
AI
offers
new
direction
impetus
SRS
by
enhancing
performance
areas
perception,
navigation,
planning,
control
strategies.
This
review
introduces
developmental
history
of
AI‐aided
summarizes
basic
architecture,
analyzes
how
can
improve
performance.
Classical
cases
impact
evidence
clinical
settings,
associated
ethical
legal
considerations
are
explored.
Finally,
challenges
discussed,
including
algorithm
development,
data
science,
human–robot
coordination,
trust
building
between
humans
robots.
Neuro-Oncology,
Journal Year:
2020,
Volume and Issue:
23(2), P. 214 - 225
Published: Oct. 13, 2020
Accurate
detection
of
brain
metastasis
(BM)
is
important
for
cancer
patients.
We
aimed
to
systematically
review
the
performance
and
quality
machine-learning-based
BM
on
MRI
in
relevant
literature.
Nature Communications,
Journal Year:
2021,
Volume and Issue:
12(1)
Published: May 13, 2021
Abstract
Although
therapies
of
cancer
are
advancing,
it
remains
challenging
for
therapeutics
to
reach
the
sites
metastasis,
which
accounts
majority
associated
death.
In
this
study,
we
have
developed
a
strategy
that
guides
an
anti-programmed
cell
death-ligand
1
(aPDL1)
antibody
accumulate
in
metastatic
lesions
promote
anti-tumour
immune
responses.
Briefly,
combination
Vadimezan
disrupts
tumour
blood
vessels
metastases
and
facilitates
recruitment
activation
adoptively
transferred
aPDL1-conjugated
platelets.
situ
activated
platelets
generate
aPDL1-decorated
platelet-derived
microparticles
(PMP)
diffuse
within
elicit
The
proposed
increases
10-fold
aPDL1
accumulation
lung
as
compared
intravenous
administration
enhances
magnitude
responses
leading
improved
antitumour
effects.
Nature Medicine,
Journal Year:
2022,
Volume and Issue:
28(4), P. 752 - 765
Published: April 1, 2022
Abstract
Whole-brain
radiotherapy
(WBRT)
is
the
treatment
backbone
for
many
patients
with
brain
metastasis;
however,
its
efficacy
in
preventing
disease
progression
and
associated
toxicity
have
questioned
clinical
impact
of
this
approach
emphasized
need
alternative
treatments.
Given
limited
therapeutic
options
available
these
poor
understanding
molecular
mechanisms
underlying
resistance
metastatic
lesions
to
WBRT,
we
sought
uncover
actionable
targets
biomarkers
that
could
help
refine
patient
selection.
Through
an
unbiased
analysis
experimental
vivo
models
metastasis
resistant
identified
activation
S100A9–RAGE–NF-κB–JunB
pathway
metastases
as
a
potential
mediator
organ.
Targeting
genetically
or
pharmacologically
was
sufficient
revert
WBRT
increase
benefits
at
lower
doses
radiation.
In
primary
melanoma,
lung
breast
adenocarcinoma
developing
metastasis,
endogenous
S100A9
levels
correlated
response
underscored
blood
noninvasive
biomarker.
Collectively,
provide
framework
personalize
improve
through
combination
radiosensitizer
balances
benefit
toxicity.
